MARKET

SGMT

SGMT

Sagimet Biosciences Inc.
NASDAQ
5.96
-0.31
-4.94%
After Hours: 6.06 +0.1 +1.59% 17:57 12/18 EST
OPEN
6.45
PREV CLOSE
6.27
HIGH
6.62
LOW
5.94
VOLUME
728.62K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
1.730
MARKET CAP
193.83M
P/E (TTM)
-3.3361
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Novan (NOVN)
TipRanks · 11h ago
Sagimet Highlights Positive MASH Combo Data and Pipeline Progress
TipRanks · 11h ago
Sagimet announces results from Phase 1 PK trial of denifanstat, resmetirom
TipRanks · 12h ago
Sagimet Reports MASH Combo Data, Eyes Phase 2 for Liver Treatment
Benzinga · 12h ago
Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH
Reuters · 12h ago
SAGIMET BIOSCIENCES INC - PHASE 2 TRIAL TO START IN 2H 2026
Reuters · 12h ago
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences
TipRanks · 1d ago
Sagimet rises as licensing deal with Teva unit targets Madrigal drug
Seeking Alpha · 1d ago
More
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Webull offers Sagimet Biosciences Inc stock information, including NASDAQ: SGMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMT stock methods without spending real money on the virtual paper trading platform.